Suppression of influenza virus replication in infected mice by protease inhibitors.
Administration of the protease inhibitors, epsilon-aminocaproic acid or aprotinins, to mice infected with mouse-adapted influenza virus strain A/PR/8/34 (HON1) and A/Aichi/2/68 (H3N2) reduced virus replication in the lungs. Up to 100-fold reduction of virus titre and virus-induced neuraminidase activity were revealed in mouse lungs under protease inhibitor treatment. As a result, drug-treated mice rapidly cleared the virus from their lungs. The predominant synthesis was of non-infectious virions with uncleaved haemagglutinin in the lungs of drug-treated mice, in contrast to the production of highly infectious virions with proteolytically cleaved haemagglutinin in untreated mice. These observations suggest that protease inhibitors suppress influenza virus replication in mouse lungs due to prevention of haemagglutinin cleavage and virus proteolytic activation.
D015119:Aminocaproic Acid / Q000627:therapeutic use; D000818:Animals; D007611:Aprotinin / Q000627:therapeutic use; D003864:Depression, Chemical; D004353:Drug Evaluation, Preclinical; D008168:Lung / Q000382:microbiology; D051379:Mice; D009975:Orthomyxoviridae / Q000187:drug effects*; D009976:Orthomyxoviridae Infections / Q000188:drug therapy* / Q000382:microbiology; D011480:Protease Inhibitors / Q000627:therapeutic use*; D014779:Virus Replication / Q000187:drug effects*
D011480:Protease Inhibitors; D007611:Aprotinin; D015119:Aminocaproic Acid